These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9243063)

  • 1. Therapy for severe community-acquired pneumonia.
    Berk SL
    Clin Infect Dis; 1997 Jul; 25(1):168-9. PubMed ID: 9243063
    [No Abstract]   [Full Text] [Related]  

  • 2. Japanese guidelines for the management of community-acquired pneumonia.
    Yanagihara K; Kohno S; Matsusima T
    Int J Antimicrob Agents; 2001; 18 Suppl 1():S45-8. PubMed ID: 11574195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Empirical antibacterial therapy of community acquired pneumonia in outpatients].
    Yakovlev SV; Suvorova MP
    Antibiot Khimioter; 1997; 42(10):23-8. PubMed ID: 9412399
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
    Aubier M; Lode H; Gialdroni-Grassi G; Huchon G; Hosie J; Legakis N; Regamey C; Segev S; Vester R; Wijnands WJ; Tolstuchow N
    J Antimicrob Chemother; 1996 May; 37 Suppl A():73-82. PubMed ID: 8737127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BTS guidelines for the management of community acquired pneumonia in adults: update 2009.
    Lim WS; Baudouin SV; George RC; Hill AT; Jamieson C; Le Jeune I; Macfarlane JT; Read RC; Roberts HJ; Levy ML; Wani M; Woodhead MA;
    Thorax; 2009 Oct; 64 Suppl 3():iii1-55. PubMed ID: 19783532
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy.
    Niven DJ; Laupland KB
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):69-81. PubMed ID: 19622058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Empiric treatment of community-acquired pneumonia].
    Fálco Ferrer V; Almirante Gragera B; Pahissa Berga A
    Rev Clin Esp; 2004 Feb; 204(2):103-5. PubMed ID: 15023311
    [No Abstract]   [Full Text] [Related]  

  • 9. Community-acquired pneumonia.
    Holmes A; Jacklin A; Impallomeni M; Rogers TR
    Lancet; 1999 May; 353(9163):1528-9. PubMed ID: 10232345
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe community-acquired pneumonia: the need to customize empiric therapy.
    Wunderink RG; Waterer GW
    Chest; 2001 Oct; 120(4):1053-5. PubMed ID: 11591535
    [No Abstract]   [Full Text] [Related]  

  • 11. Community-acquired pneumonia: new guidelines for management.
    File TJ
    Curr Opin Infect Dis; 2001 Apr; 14(2):161-4. PubMed ID: 11979127
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs of choice for community-acquired bacterial pneumonia.
    Med Lett Drugs Ther; 2007 Jul; 49(1266):62-4. PubMed ID: 17652999
    [No Abstract]   [Full Text] [Related]  

  • 13. Community acquired pneumonia in elderly people. Addition of erythromycin is not currently justified.
    Woodhead M
    BMJ; 1998 Nov; 317(7171):1524. PubMed ID: 9831595
    [No Abstract]   [Full Text] [Related]  

  • 14. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
    Bartlett JG
    Semin Respir Infect; 1997 Dec; 12(4):329-33. PubMed ID: 9436960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical treatment of nonsevere community-acquired pneumonia: still a difficult issue.
    Torres A; Ausina V
    Eur Respir J; 1995 Dec; 8(12):1996-8. PubMed ID: 8666092
    [No Abstract]   [Full Text] [Related]  

  • 16. Neonatal community-acquired pneumonia: pathogens and treatment.
    Wang H; Tang J; Xiong Y; Li X; Gonzalez F; Mu D
    J Paediatr Child Health; 2010 Nov; 46(11):668-72. PubMed ID: 20796185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How far should we go in reducing the length of antibiotic therapy for community-acquired pneumonia?].
    Mayaud C; Souidi A; Fartoukh M; Parrot A
    Rev Pneumol Clin; 2005 Apr; 61(2):61-6. PubMed ID: 16012359
    [No Abstract]   [Full Text] [Related]  

  • 18. Aetiology and resistance patterns of community-acquired pneumonia in León, Nicaragua.
    Matute AJ; Brouwer WP; Hak E; Delgado E; Alonso E; Hoepelman IM
    Int J Antimicrob Agents; 2006 Nov; 28(5):423-7. PubMed ID: 17046211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empiric Meropenem-based versus Ceftazidime-based Therapy for Severe Community-Acquired Pneumonia in a Retrospective Cohort Study.
    Chua NG; Liew YX; Lee W; Tang SS; Zhou YP; Patel K; Kwa AL; Chlebicki MP
    Ann Acad Med Singap; 2019 Mar; 48(3):98-103. PubMed ID: 30997479
    [No Abstract]   [Full Text] [Related]  

  • 20. The choice of antibacterial drugs.
    Med Lett Drugs Ther; 1998 Mar; 40(1023):33-42. PubMed ID: 9549552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.